Effects of Caffeine on Methacholine Challenge and Exhaled Nitric Oxide Levels.

This study has been completed.
Information provided by:
University of Saskatchewan
ClinicalTrials.gov Identifier:
First received: January 26, 2010
Last updated: October 5, 2010
Last verified: October 2010

To investigate whether or not the ingestion of caffeine with alter airway responsiveness to methacholine and/or change the level of exhaled nitric oxide.

Condition Intervention
Other: caffeine
Other: No caffeine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: The Effects of Caffeine on Exhaled Nitric Oxide Levels and Methacholine PC20

Resource links provided by NLM:

Further study details as provided by University of Saskatchewan:

Primary Outcome Measures:
  • methacholine pc20 [ Time Frame: 1 hour post ingestion ] [ Designated as safety issue: No ]

Estimated Enrollment: 15
Study Start Date: January 2010
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: coffee with caffeine Other: caffeine
Starbuck's Grande Pike Roast coffee
Placebo Comparator: decaffeinated coffee
Starbuck's Grande Pike Roast Decaf
Other: No caffeine
Starbuck's Grande Pike Roast Decaffeinated Coffee


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnosis of asthma
  • FEV1 greater than 65%

Exclusion Criteria:

  • asthma is poorly controlled
  • presence of other airway disease (e.g. COPD)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01057875

Canada, Saskatchewan
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 0W8
Sponsors and Collaborators
University of Saskatchewan
Principal Investigator: Donald W Cockcroft, MD University of Saskatchewan
  More Information

No publications provided by University of Saskatchewan

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Donald Cockcroft, MD, University of Saskatchewan
ClinicalTrials.gov Identifier: NCT01057875     History of Changes
Other Study ID Numbers: BIO REB 09-186
Study First Received: January 26, 2010
Last Updated: October 5, 2010
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Central Nervous System Agents
Central Nervous System Stimulants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Purinergic Agents
Purinergic Antagonists
Purinergic P1 Receptor Antagonists
Therapeutic Uses

ClinicalTrials.gov processed this record on March 30, 2015